MiR Scientific: Erik Johnson, Rob Tenniswood

MiR Scientific, a developer of noninvasive cancer tests with a focus on urological cancers, has appointed Erik Johnson as chief operating officer. Johnson joins the company from Bristol Myers Squibb, where he was head of worldwide commercial, immuno-oncology melanoma & genitourinary, and served as worldwide lead for Opdivo and Yervoy in those tumors.

MiR Scientific also said that Rob Tenniswood, the firm’s scientific cofounder and first chief operating officer, will be promoted to the role of executive vice chairman.